Technological Enhancements and Business Validation Toward International Development of Microbial Gene **Database** (bitBiome, Inc.)

EbitBiome

City	Year of Establishment	Founder
Shinjuku, Tokyo	2018	Masahito Hosokawa, Ph. D.

Partner VC	Latest round of Fundraising	Valuation	
_	Series B2	Non-Disclosure	

Contact Information :

tel: 03-6205-5662 e-mai : info@bitbiome.bio

Website : https://bitbiome.bio

O Business Plan

bitBiome, Inc. contributes to solving R&D and production issues in the bio-manufacturing industry through the realization of the discovery and improvement of optimal genes by using our core technologies: the one and only single-cell genome analysis technology "bit-MAP[®]", a vast and highly accurate microbial genome database "bit-GEM", an enzyme discovery and modification platform with world-class accuracy and speed "bit-QED". This grant project aims to support entry into the primary market for biomanufacturing utilizing microbial gene resources in the United States. It involves the improvement of our microbial single-cell genome sequencing technologies that enable efficient analysis of overseas environmental samples.

• Research Outline

In this R&D effort, we will improve our existing microbial genome analysis technology to enable efficient analysis of environmental samples, adapt it to the U.S. market, and also demonstrate its performance and feasibility for commercialization.

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Food & Agriculture	PCA 2023~2027FY	JPY 440 million	United States

OInternational collaborative technology demonstration

Local base establishment

• Supply chain development

collection performance of overseas environmental samples using the improved technology.

Through the international demonstration activities, we will investigate the feasibility of commercialization in the U.S. market, clarify the necessary technical specifications, and then improve the technology and implement it overseas. The following activities will be undertaken: 1) research on business feasibility and regulations, 2) development of lab or office in the U.S., and 3) demonstration of microbial genome analysis and genetic data